ScripThe biggest upcoming catalysts for NewAmsterdam Pharma’s CETP inhibitor obicetrapib as a means for lowering low-density lipoprotein cholesterol (LDL-C) are regulatory submissions later this year based
ScripAlzheimer’s disease (AD) drug development during the last several years showed that amyloid-clearing medicines worked best in patients treated early in their disease progression, and the first two ant
ScripEisai reported its fiscal year 2024 earnings on 15 May for the 12 months ended 31 March, which included fiscal year 2025 guidance for its most scrutinized product, the anti-amyloid antibody Leqembi (l